Zobrazeno 1 - 10
of 71
pro vyhledávání: '"E. Giangreco"'
Autor:
F.S. Macaluso, M. Grova, F. Mocciaro, R. Di Mitri, A. Privitera, M. Distefano, A. Vitello, S. Camilleri, C. Ferracane, D. Pluchino, N. Belluardo, E. Giangreco, W. Fries, A. Viola, M. Cappello, L. D'Amato, C. Bertolami, M. Ventimiglia, S. Renna, A. Casa, S. De Vivo, A. Orlando
Publikováno v:
Digestive and Liver Disease. 55:S159-S160
Autor:
F.S. Macaluso, E. D'Antonio, W. Fries, A. Viola, O. Ksissa, M. Cappello, S. Muscarella, N. Belluardo, E. Giangreco, F. Mocciaro, R. Di Mitri, C. Ferracane, A. Vitello, M. Grova, S. Renna, A. Casa, M. Ventimiglia, A. Orlando
Publikováno v:
Digestive and Liver Disease. 55:S178
Autor:
A. Trovatello, Giulia Rizzuto, Marco Ventimiglia, E. Giangreco, Andrea Centritto, R. Orlando, Fabio Salvatore Macaluso, Giovita Piccillo, Maria Cappello, E. Giuffrida, C. Bertolami, Walter Fries, R. Vassallo, S. Camilleri, A. Magnano, Sara Renna, Ambrogio Orlando, Anna Viola, Antonino Carlo Privitera, N. Belluardo, Elisa Vinci, S. Garufi
Publikováno v:
Inflammatory Bowel Diseases. 27:182-189
Background No data on the recently introduced infliximab (IFX) biosimilar SB2 in inflammatory bowel disease (IBD) are available. Methods The Sicilian Prospective Observational Study of Patients With IBD Treated With Infliximab Biosimilar SB2 is a mul
Autor:
F.S. Macaluso, M. Grova, M. Saladino, M.G. Demarzo, A.C. Privitera, E. Giangreco, S. Garufi, S. Renna, A. Casà, M. Ventimiglia, M. Cappello, W. Fries, A. Orlando
Publikováno v:
Digestive and Liver Disease. 54:S93-S94
Autor:
F S Macaluso, M Grova, M Saladino, M G Demarzo, A C Privitera, E Giangreco, S Garufi, S Renna, A Casà, M Ventimiglia, M Cappello, W Fries, A Orlando
Publikováno v:
Journal of Crohn's and Colitis. 16:i359-i360
Background There is no head-to-head trial comparing ustekinumab (UST) and vedolizumab (VDZ) in Crohn’s disease (CD). Recently, real-world studies evaluated the two biologics in patients refractory to anti-TNF therapy, i.e. as second-line agents. Co
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Fabio Salvatore Macaluso, A. Magnano, Sara Renna, Marco Ventimiglia, Ambrogio Orlando, Elisa Vinci, C. Ferracane, Giulia Rizzuto, B. Scrivo, Giovita Piccillo, Francesco Graziano, Claudio Romano, A. Casà, S. Garufi, Walter Fries, C. Bertolami, Maria Cappello, Anna Viola, Giuseppe Costantino, Giulia Teresi, Antonino Carlo Privitera, N. Belluardo, E. Giangreco, Michele Citrano, A. Busacca
Publikováno v:
Journal of gastroenterology and hepatologyReferences. 36(11)
BACKGROUND AND AIM There are few clinical data on Adalimumab (ADA) biosimilars in inflammatory bowel disease. We aimed to perform a multicenter, observational, prospective study on safety and effectiveness of ADA biosimilar ABP 501 in patients with i
Autor:
A.C. Privitera, Maria Cappello, Giuseppe Costantino, Giulia Rizzuto, Corrado Romano, E. Vinci, S. Garufi, A. Magnano, N. Belluardo, Sara Renna, Michele Citrano, Anna Viola, Walter Fries, E. Giangreco, A. Busacca, A. Casà, C. Bertolami, Marco Ventimiglia, G. Piccillo, A. Orlando, C. Ferracane, F. Graziano, Fabio Salvatore Macaluso, B. Scrivo
Publikováno v:
Digestive and Liver Disease. 53:S162-S163
Autor:
Marcello Maida, A. Casà, Walter Fries, Anna Viola, S. Camilleri, Maria Cappello, N. Belluardo, R. Di Mitri, Mauro Grova, A. Magnano, F. Mocciaro, A. Orlando, A.C. Privitera, E. Giangreco, C. Ferracane, Sara Renna, G. Piccillo, S. Garufi, Federica Crispino, Fabio Salvatore Macaluso
Publikováno v:
Digestive and Liver Disease
Autor:
S. Garufi, Giulia Rizzuto, Fabio Salvatore Macaluso, G. Piccillo, A.C. Privitera, F. Graziano, A. Magnano, E. Giangreco, Marco Ventimiglia, Sara Renna, B. Scrivo, A. Casà, A. Orlando, C. Bertolami, C. Ferracane, Maria Cappello, Giuseppe Costantino, Michele Citrano, Corrado Romano, Walter Fries, A. Busacca, E. Vinci, Anna Viola, N. Belluardo
Publikováno v:
Journal of Crohn's and Colitis. 15:S437-S438
Background Clinical data on the use of Adalimumab (ADA) biosimilar ABP 501 in inflammatory bowel disease (IBD) are lacking. Methods SPOSAB ABP 501 is a multicenter, observational, prospective study performed among the cohort of the Sicilian Network f